Proteins for life
ExpreS2ion develops a portfolio of vaccines for diseases such as COVID-19, influenza and breast cancer through the use of its non-viral Drosophila S2 cells-based expression system, ExpreS2, that is recognized for handling even the toughest protein challenges.
The company also collaborates on additional projects, including several malaria vaccines, and offers a range of protein expression and production services from discovery to pre-clinical development and cGMP production.
Latest press release
Warrants of series TO5 were subscribed to approximately 97.4 percent and ExpreS2ion receives approximately SEK 44.3 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SINGAPORE, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.…
Read more